NCT03943862 (2Share) is a Phase 2 clinical trial of 2Share in History of Suicide Attempt, sponsored by University of Ulm.

Who is sponsoring NCT03943862?

NCT03943862 is sponsored by University of Ulm.

What drugs are being tested in NCT03943862?

Interventions in NCT03943862: 2Share.

What condition does NCT03943862 study?

NCT03943862 studies History of Suicide Attempt.

Is NCT03943862 still recruiting?

NCT03943862 is currently terminated. Last updated 13 March 2020.

Last reviewed 2020-03-13 · How we verify

NCT03943862: 2Share

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Share Or Not To Share

Terminated Phase 2 Last updated 13 March 2020

What this trial tests

Phase 2 trial testing 2Share in History of Suicide Attempt in 4 participants. Terminated before completion.

Timeline

7 May 2019

Primary endpoint
1 January 2020

1 March 2020

Quick facts

Lead sponsor	University of Ulm
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	7 May 2019
Primary completion	1 January 2020
Estimated completion	1 March 2020
Sites	1 location across Germany

Drugs / interventions tested

2Share

Conditions studied

History of Suicide Attempt — all drugs for History of Suicide Attempt →

Sponsor

University of Ulm

Who can join

18 and older, any sex, with History of Suicide Attempt. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the group-based intervention "To Share Or Not To Share" in a German clinical setting. Feasibility and efficacy of the program will be tested in a pilot randomized-controlled trial.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Psychosocial interventions for self-harm in adults.
Witt KG, Hetrick SE, Rajaram G, Hazell P, et al · · 2021 · cited 79× · PMID 33884617 · DOI 10.1002/14651858.cd013668.pub2
Honest, Open, Proud to support disclosure decisions and to decrease stigma's impact among people with mental illness: conceptual review and meta-analysis of program efficacy.
Rüsch N, Kösters M. · · 2021 · cited 35× · PMID 33893512 · DOI 10.1007/s00127-021-02076-y

Verify or expand the search:

Other University of Ulm trials

Trials by the same sponsor.

NCT07436195 — Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA · recruiting
NCT07154524 — Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · recruiting
NCT06877143 — Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis · NA · recruiting
NCT06280079 — Ultra-high-caloric, Fatty Diet in ALS · NA · recruiting
NCT06627348 — Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03943862 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Ulm
Last refreshed: 13 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03943862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing